LNTH Lantheus Holdings Inc

Lantheus Holdings to Host First Quarter 2021 Earnings Conference Call and Webcast on May 4, 2021 at 8:00 a.m. Eastern Time

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--

(the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Tuesday, May 4, 2021, to discuss its financial and operating results for the first quarter of 2021.

To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1‑678-509-7599 (international callers) and provide passcode 9275247. A live webcast will also be available in the Investors section of the Company’s website at .

A replay of the webcast will be available in the Investors section of the Company’s website approximately two hours after completion of the call and will be archived for 30 days.

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden. For more information, visit .

EN
20/04/2021

Underlying

LNTHLantheus Holdings Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lantheus Holdings Inc

 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Host First Quarter 2024 Earnings Conference Call and Webca...

Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024, to discuss its financial and operating results for the first quarter of 2024. To access the conference call or webcast, participants should register online at . To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be avai...

11h / 26m 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Present at the Leerink Partners Global Biopharma Conferenc...

Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024 BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the Leerink Partners Global Biopharma Conference 2024 at 9:20 a.m. ET on Tuesday, March 12. To access a live webcast of the presentation, please visit the  section of the Company’s website at . A repla...

March 5, 2024 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Mic...

Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients DEFINITY is the #1 utilized ultrasound enhancing agent in the U.S. for patients with suboptimal echocardiograms BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow® disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA)...

March 4, 2024 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Offi...

Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer BEDFORD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the promotion of Amanda Morgan to Chief Commercial Officer and her elevation to be a member of the company’s Executive Team, effective March 25, 2024. In her role, Ms. Morgan will continue to lead the Company’s commercial strategy and activities, incl...

February 28, 2024 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Present at the TD Cowen 44th Annual Health Care Conference

Lantheus to Present at the TD Cowen 44th Annual Health Care Conference BEDFORD, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the TD Cowen 44th Annual Health Care Conference at 10:30 a.m. ET on Monday, March 4. To access a live webcast of the presentation, please visit the  section of the Company’s website at . A replay of the webca...

February 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch